Performance of adjuvant treatment correlates with survival in reoperated glioblastomas

ABSTRACT

Objective To analyze cases of recurrent glioblastoma subjected to reoperation at a Brazilian public healthcare service.

Methods A total of 39 patients subjected to reoperation for recurrent glioblastoma at the Department of Neurosurgery, São Paulo Hospital, Federal University of São Paulo, from January 2000 to December 2013 were retrospectively analyzed.

Results The median overall survival was 20 months (95% confidence interval – CI = 14.9–25.2), and the median survival after reoperation was 9.1 months (95%CI: 2.8–15.4). The performance of adjuvant treatment after the first operation was the single factor associated with overall survival on multivariate analysis (relative risk – RR = 0.3; 95%CI = 0.2–0.7); p = 0.005).

Conclusion The length of survival of patients subjected to reoperation for glioblastoma at a Brazilian public healthcare service was similar to the length reported in the literature. Reoperation should be considered as a therapeutic option for selected patients.

RESUMO

Objetivo Analisar o papel da reoperação em pacientes com glioblastoma recidivado em um serviço público no Brasil.

Métodos Foram analisados retrospectivamente 39 pacientes submetidos à reoperação por recorrência de glioblastoma no Departamento de Neurocirurgia da Universidade Federal de São Paulo, no período de janeiro de 2000 até dezembro de 2013.

Resultados A sobrevida global mediana foi de 20 meses (IC 95% = 14.9–25.2), e a sobrevida mediana após a reoperação foi de 9.1 meses (IC 95% = 2.8–15.4). A realização de tratamento adjuvante após a primeira cirurgia foi o único fator associado com a sobrevida global numa análise multivariada (RR = 0.3; IC 95% = 0.2–0.7; p = 0.005).

Conclusão A sobrevida dos pacientes submetidos à reoperação em um serviço público no Brasil é semelhante à reportada pela literatura. A reoperação deve ser considerada como uma opção terapêutica em pacientes selecionados.

glioblastoma - reoperation - general surgery - survival

glioblastoma - reoperação - cirurgia geral - sobrevivência

Publication History

Received: 04 February 2016

Accepted: 09 August 2016

Article published online:
06 September 2023

• References

• 1 Egan KM, Thompson RC, Nabors LB, Olson JJ, Brat DJ, Larocca RV et al. Cancer susceptibility variants and the risk of adult glioma in a US case-control study. J Neuroncol. 2011;104(2):535-42. doi:10.1007/s11060-010-0506-0
• 2 Stupp R, Mason WP, Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med. 2005;352(10):987-96. doi:10.1056/NEJMoa043330
• 3 Darefsky AS, King JT, Jr., Dubrow R. Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of surveillance, epidemiology, and end results registries. Cancer. 2012;118(8):2163-72. doi:10.1002/cncr.26494
• 4 Stupp R, Hegi ME, Mason WP, Bent MJ, Taphoorn MJ, Janzer RC et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet. Oncology. 2009;10(5):459-66. doi:10.1016/S1470-2045(09)70025-7
• 5 Helseth R, Helseth E, Johannesen TB, Langberg CW, Lote K, Rønning P et al. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand. 2010;122(3):159-67. doi:10.1111/j.1600-0404.2010.01350.x
• 6 Krex D, Klink B, Hartmann C, Deimling A, Pietsch T, Simon M et al. Long-term survival with glioblastoma multiforme. Brain. 2007;130(10):2596-606. doi:10.1093/brain/awm204
• 7 Ringel F, Pape H, M, Krex D, Bock HC, Misch M et al. Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. Neuro-oncol. 2016;18(1):96-104. doi:10.1093/neuonc/nov145
• 8 Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190-8. doi:10.3171/jns.2001.95.2.0190
• 9 Samis Zella MA, Wallocha M, Slotty PJ, Isik G, Hänggi D, Schroeteler J et al. Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma. Acta Neurochir (Wien). 2014;156(2):313-23. doi:10.1007/s00701-013-1931-6
• 10 Hong B, Wiese B, Bremer M, Heissler HE, Heidenreich F, Krauss JK et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme. Am J Clin Oncol. 2013;36(3):261-8. doi:10.1097/COC.0b013e3182467bb1
• 11 Barbagallo GM, Jenkinson MD, Brodbelt AR. “Recurrent” glioblastoma multiforme, when should we reoperate? Br J Neurosurg. 2008;22(3):452-55. doi:10.1080/02688690802182256
• 12 Chaichana KL, Zadnik P, Weingart JD, Olivi A, Gallia GL, Blakeley J et al. Multiple resections for patients with glioblastoma: prolonging survival. J Neurosurg. 2013;118(4):812-20. doi:10.3171/2012.9.JNS1277
• 13 Sughrue ME, Sheean T, Bonney PA, Maurer AJ, Teo C. Aggressive repeat surgery for focally recurrent primary glioblastoma: outcomes and theoretical framework. Neurosurg Focus. 2015;38(3):E11. doi:10.3171/2014.12.FOCUS14726
• 14 Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF et al. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncol. 2011;13(10):1118-24. doi:10.1093/neuonc/nor110
• 15 Filippini G, Falcone C, Boiardi A, Broggi G, Bruzzone MG, Caldiroli D et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro-oncol. 2008;10(1):79-87. doi:10.1215/15228517-2007-038
• 16 Gorlia T, Stupp R, Brandes AA, Rampling RR, Fumoleau P, Dittrich C et al. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer. 2012;48(8):1176-84. doi:10.1016/j.ejca.2012.02.004
• 17 McNamara MG, Lwin Z, Jiang H, Templeton AJ, Zadeh G, Bernstein M et al. Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression. J Neurooncol. 2014;117(1):147-52. doi:10.1007/s11060-014-1366-9
• 18 Ryken TC, Kalkanis SN, Buatti JM, Olson JJ. The role of cytoreductive surgery in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2014;118(3):479-88. doi:10.1007/s11060-013-1336-7
• 19 Quick J, Gessler F, Dützmann S, Hattingen E, Harter PN, Weise LM et al. Benefit of tumor resection for recurrent glioblastoma. J Neurooncol. 2014;117(2):365-72. doi:10.1007/s11060-014-1397-2
• 20 Stark AM, Nabavi A, Mehdorn HM, Blömer U. Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol. 2005;63(2):162-69. doi:10.1016/j.surneu.2004.01.028
• 21 Stark AM, Bergh J, Hedderich J, Mehdorn HM, Nabavi A. Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients. Clin Neurol Neurosurg. 2012;114(7):840-5. doi:10.1016/j.clineuro.2012.01.026
• 22 Yong RL, Wu T, Mihatov N, Shen MJ, Brown MA, Zaghloul KA et al. Residual tumor volume and patient survival following reoperation for recurrent glioblastoma. J Neurosurg. 2014;121(4):802-9. doi:10.3171/2014.6.JNS132038
• 23 Oppenlander ME, Wolf AB, Snyder LA, Bina R, Wilson JR, Coons SW et al. An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. J Neurosurg. 2014;120(4):846-53. doi:10.3171/2013.12.JNS13184
• 24 Blumenthal DT, Won M, Mehta MP, Curran WJ, Souhami L, Michalski JM et al. Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database. J Clin Oncol. 2009;27(5):733-9. doi:10.1200/JCO.2008.18.9035
• 25 Valduvieco I, Verger E, Bruna J, Caral L, Pujol T, Ribalta T et al. Impact of radiotherapy delay on survival in glioblastoma. Clin Transl Oncol. 2013;15(4):278-82. doi:10.1007/s12094-012-0916-x
• 26 Graus F, Bruna J, Pardo J, Escudero D, Vilas D, Barceló I et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain. Neuro-oncol. 2013;15(6):797-805. doi:10.1093/neuonc/not013
• 27 Spratt DE, Folkert M, Zumsteg ZS, Chan TA, Beal K, Gutin PH et al. Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma. J Neurooncol. 2014;116(2):357-63. doi:10.1007/s11060-013-1302-4
• 28 Loureiro LV, Pontes LB, Callegaro-Filho D, Koch LO, Weltman E, Victor ES et al. Waiting time to radiotherapy as a prognostic factor for glioblastoma patients in a scenario of medical disparities. Arq Neuro-psiquiatr. 2015;73(2):104-10. doi:10.1590/0004-282X20140202
• 29 Chen Z, King W, Pearcey R, Kerba M, Mackillop WJ. The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature. Radiother Oncol. 2008;87(1):3-16. doi:10.1016/j.radonc.2007.11.016
• 30 Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL et al. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-oncology. 2015;17(8):1051-63. doi:10.1093/neuonc/nov031